Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Prostate Cancer
Inify, Karolinska Institutet partner on AI-driven prostate cancer diagnostics
By
LabPulse.com staff writers
Digital pathology firm Inify Laboratories is collaborating with scientists at the Karolinska Institutet in Stockholm on a project aimed at improving the precision of prostate cancer diagnosis through artificial intelligence (AI)-driven image analysis.
November 5, 2024
AI model shows promise for 'virtual staining' of cancerous tissue
By
LabPulse.com staff writers
Researchers have created an artificial intelligence (AI) model that generates images showing virtual colorations of cancerous tissue.
September 12, 2024
Veracyte to share bundle of genomic classifier studies at AUA 2024
By
LabPulse.com staff writers
Veracyte has announced that the American Urological Association's May meeting will feature nine sessions related to evaluations of its prostate cancer and bladder cancer genomic tests.
April 16, 2024
Lipid enzyme blocker renders prostate cancer cells vulnerable to PARP inhibitors in study
By
Nick Paul Taylor
Blocking lipid synthesis enhanced the effect of PARP inhibitors on prostate cancer in a preclinical study, pointing to a potential way to make the treatments effective in more patients.
April 15, 2024
Study: AI assists discovery of prostate cancer subtypes
By
Matt Limb
Prostate tumors have been found to evolve along multiple pathways, leading to two distinct disease types with “pivotal” implications for diagnosis and treatment, say scientists.
March 8, 2024
Weill Cornell study may support new prognostic test for prostate tumor spread
By
LabPulse.com staff writers
Scientists working in the department of pathology and laboratory medicine at Weill Cornell Medicine have found that certain noncancerous cells may be useful for assessing prostate tumors and their potential to spread.
January 16, 2024
Targeting feeder cells reverses prostate cancer’s resistance to treatment in study
By
Matt Limb
Scientists have found a way to reverse prostate cancer’s resistance to drugs in research, which they say could have a broad impact across multiple cancer types.
October 24, 2023
Foundation Medicine wins FDA approval for companion diagnostic to prostate cancer treatment
By
Nick Paul Taylor
FoundationOne CDx analyzes more than 300 cancer-related genes for genomic alterations. The ability of the product to test for alterations and select gene rearrangements and genomic signatures has led to its approval as a CDx for multiple products.
August 16, 2023
Veracyte raises full-year outlook on prostate cancer growth, reveals executive is leaving
By
Nick Paul Taylor
In the second quarter, Veracyte reported sales of 15,000 Decipher Prostate tests. The 50% year-over-year increase in test volumes helped the company to report total sales of $90.3 million.
August 11, 2023
Quest Diagnostics teams up with Envision Science on prostate cancer biomarkers
By
Matt Limb
The test aims to improve the accuracy of grading biopsies for prostate cancer, which is one of the most prevalent and deadly cancers affecting men.
July 27, 2023
Quest launches biomarker test to improve grading of prostate cancer biopsies
By
Nick Paul Taylor
Building on the Australian research and working with Envision Sciences, the Australian diagnostics company that owns the biomarker intellectual property, Quest’s subspecialty pathology business, AmeriPath, has developed a tissue-based test.
July 17, 2023
At ASCO meeting, Veracyte highlights prostate cancer study data using genomics database
By
LabPulse.com staff writers
The Decipher GRID database, which is used by Veracyte and its partners in urologic cancer research, comprises more than 100,000 whole-transcriptome profiles from patients with urologic cancers.
May 30, 2023
Page 1 of 8
Next Page
